Fukuoka, Kurume, Japan Clinical Trials

A listing of Fukuoka, Kurume, Japan clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 75 clinical trials
Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.

Kurume University Hospital
 (0.6 away) Contact site
  • 40 views
  • 16 May, 2021
  • +118 other locations
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with unresected stage I or IIA non-small cell lung cancer (NSCLC). The primary study hypotheses are: SBRT plus pembrolizumab prolongs Event-free Survival (EFS) compared …

lung carcinoma
pembrolizumab
mk-3475
stereotactic body radiation therapy
Kurume University Hospital ( Site 2815)
 (0.6 away) Contact site
  • 121 views
  • 16 Jun, 2021
  • +172 other locations
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence.

bevacizumab
durvalumab
Research Site
 (0.6 away) Contact site
  • 75 views
  • 16 Jun, 2021
  • +242 other locations
Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.

The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of antiplatelet therapy in patients following a recent non cardioembolic ischemic stroke which occurs when a …

St.Mary's Hospital
 (1.0 away) Contact site
  • 45 views
  • 10 Jun, 2021
  • +261 other locations
Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to assess the efficacy of etrasimod on clinical remission in participants with moderately to severely active ulcerative colitis (UC).

remission
endoscopy
Kurume University Hospital
 (0.6 away) Contact site
  • 12 views
  • 06 Jun, 2021
  • +414 other locations
Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

The primary objective of the study is to determine if treatment with high-dose aflibercept (HD) at intervals of 12 or 16 weeks provides non-inferior best corrected visual acuity (BCVA) compared to aflibercept dosed every 8 weeks. The secondary objectives of the study are as follows: To determine the effect of …

swelling
corrected visual acuity
diabetic eye disease
diabetic macular edema
visual impairment
Regeneron Study Site
 (0.6 away) Contact site
  • 17 views
  • 14 May, 2021
  • +199 other locations
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior …

hepatitis
lenvatinib
metastatic hepatocellular carcinoma
chemoembolization
TACE
Kurume University Hospital ( Site 0362)
 (0.6 away) Contact site
  • 79 views
  • 16 Jun, 2021
  • +166 other locations
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC. The patients cannot be eligible for locoregional therapy.

systemic therapy
sorafenib
durvalumab
cancer
liver cancer
Research Site
 (0.0 away) Contact site
  • 272 views
  • 10 Jun, 2021
  • +247 other locations
A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in participants with moderately and severely active Crohn's disease (CD).

abdominal pain
mucosal inflammation
immunosuppressive agents
endoscopy
corticosteroids
Kurume University Hospital /ID# 166012
 (0.6 away) Contact site
  • 824 views
  • 02 Jun, 2021
  • +730 other locations
Study of Amivantamab a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

The purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of Amivantamab as a monotherapy and in combination with lazertinib, and to determine the recommended Phase 2 dose (RP2D) (monotherapy), recommended Phase 2 combination dose (RP2CD) (combination therapy), and to determine recommended Phase 2 Dose (RP2q3W) with …

EGFR
tyrosine
epidermal growth factor
cancer chemotherapy
measurable disease
Kurume University Hospital
 (0.6 away) Contact site
  • 0 views
  • 24 May, 2021
  • +105 other locations